The MLLT6 antibody is designed to target the MLLT6 protein, also known as AF17. a member of the mixed lineage leukemia (MLL) translocation partner family. MLLT6 is a nuclear protein implicated in transcriptional regulation and chromatin remodeling through its association with the MLL histone methyltransferase complex. This complex plays a critical role in maintaining histone H3 lysine 4 (H3K4) methylation, a key epigenetic mark for active gene promoters. MLLT6 contains a conserved YEATS domain, which binds acetylated histones, suggesting its role in recognizing modified chromatin states. Dysregulation of MLLT6. often due to chromosomal translocations involving the MLL gene (e.g., MLL-MLLT6 fusions in acute leukemias), disrupts normal epigenetic programming, leading to aberrant gene expression and oncogenesis. Antibodies against MLLT6 are widely used in research to study its expression patterns, subcellular localization, and interactions within transcriptional complexes. They are essential tools in leukemia research, particularly for identifying MLL rearrangement-related malignancies, as well as exploring its broader functions in development and cancer. Validation of MLLT6 antibodies typically includes Western blotting, immunofluorescence, and immunohistochemistry, with attention to specificity due to structural similarities among MLLT family members.